EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Pilot clinical trial of macimorelin to assess safety and efficacy in patients with cancer cachexia

Megan Herodes iD, Lindsey J Anderson, Samuel Shober, Ellen A Schur, Solomon A Graf, Nicola Ammer, Ramiro Salas, Marco Marcelli, Jose M Garcia iD

Journal of Cachexia, Sarcopenia and Muscle · 2023

DOI: 10.1002/jcsm.13191 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2023. Verfasst von Megan Herodes und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gerontology and Geriatric Medicine, School of Medicine, University of Washington, Seattle, WA, USA. Hauptthemen laut MEDLINE: Cachexia, Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, BLRD VA, RRD VA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cancer cachexia is associated with reduced body weight, appetite and quality of life (QOL) with no approved treatments. Growth hormone secretagogues like macimorelin have potential to mitigate these effects.

Methods

This pilot study assessed the safety and efficacy of macimorelin for 1 week. Efficacy was defined a priori as 1‐week change in body weight (≥0.8 kg), plasma insulin‐like growth factor (IGF)‐1 (≥50 ng/mL) or QOL (≥15%). Secondary outcomes included food intake, appetite, functional performance, energy expenditure and safety laboratory parameters. Patients with cancer cachexia were randomized to 0.5 or 1.0 mg/kg macimorelin or placebo; outcomes were assessed non‐parametrically.

Results

Participants receiving at least one of either macimorelin dose were combined ( N = 10; 100% male; median age = 65.50 ± 2.12) and compared with placebo ( N = 5; 80% male; median age = 68.00 ± 6.19). Efficacy criteria achieved: body weight (macimorelin N = 2; placebo N = 0; P = 0.92); IGF‐1 (macimorelin N = 0; placebo N = 0); QOL by Anderson Symptom Assessment Scale (macimorelin N = 4; placebo N = 1; P = 1.00) or Functional Assessment of Chronic Illness Therapy‐Fatigue (FACIT‐F; macimorelin N = 3; placebo N = 0; P = 0.50). No related serious or non‐serious adverse events were reported. In macimorelin recipients, change in FACIT‐F was directly associated with change in body weight ( r = 0.92, P = 0.001), IGF‐1 ( r = 0.80, P = 0.01), and caloric intake ( r = 0.83, P = 0.005), and inversely associated with change in energy expenditure ( r = −0.67, P = 0.05).

Conclusions

Daily oral macimorelin for 1 week was safe and numerically improved body weight and QOL in patients with cancer cachexia compared with placebo. Longer term administration should be evaluated for mitigation of cancer‐induced reductions in body weight, appetite and QOL in larger studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CachexiaNeoplasmsHumansMaleMiddle AgedAgedFemaleInsulin-Like Growth Factor IQuality of LifePilot ProjectsBody WeightIndolesTryptophan

Stichwörter der Autor:innen

appetitecancer cachexiaghrelin receptor agonistgrowth hormone secretagoguemacimorelin

Substanzen

Insulin-Like Growth Factor ImacimorelinIndolesTryptophan

Autor:innen und Institutionen

  • Division of Gerontology and Geriatric Medicine, School of Medicine, University of Washington, Seattle, WA, USA.
  • Geriatric Research, Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA.
  • Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, WA, USA.
  • Hospital and Specialty Medicine, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA.
  • Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.
  • Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.

ORCID-Profile: Megan Herodes, Jose M Garcia

Förderung

  • NIDDK NIH HHS
  • BLRD VA
  • RRD VA
  • NIAMS NIH HHS
  • CSRD VA
  • NIA NIH HHS
  • NCI NIH HHS
  • U.S. Department of Veterans Affairs

Zitieren

APA

Herodes, M., Anderson, L. J., Shober, S., Schur, E. A., Graf, S. A., Ammer, N., Salas, R., Marcelli, M., & Garcia, J. M. (2023). Pilot clinical trial of macimorelin to assess safety and efficacy in patients with cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.13191

Vancouver

Herodes M, Anderson LJ, Shober S, Schur EA, Graf SA, Ammer N, et al. Pilot clinical trial of macimorelin to assess safety and efficacy in patients with cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle. 2023. doi:10.1002/jcsm.13191

BibTeX
@article{Herodes2023,
  author = {Herodes, Megan and Anderson, Lindsey J and Shober, Samuel and Schur, Ellen A and Graf, Solomon A and Ammer, Nicola and Salas, Ramiro and Marcelli, Marco and Garcia, Jose M},
  title = {Pilot clinical trial of macimorelin to assess safety and efficacy in patients with cancer cachexia},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  year = {2023},
  doi = {10.1002/jcsm.13191}
}
Kostenlos starten →